Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158824 | 0.91 | — | — | |
| SCHEMBL17449863 | 0.91 | — | — | |
| SCHEMBL14073677 | 0.87 | PRMT3 (0.31) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL26652081 | 0.85 | — | — | |
| SCHEMBL10047099 | 0.85 | KDM4A (0.37) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL23951850 | 0.84 | PRMT3 (0.31) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL22644635 | 0.84 | PRMT3 (0.31) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24227052 | 0.83 | — | — | |
| SCHEMBL260446 | 0.83 | ALDH1A1 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24036624 | 0.83 | PRMT3 (0.33) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | CIVI BIOPHARMA INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-11912779-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11839624-B2 | Micellar nanoparticles and uses thereof | BIORCHESTRA CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-11833254-B2 | Discoidal nano universal platform for efficient delivery of PNAs | UNIVERSITY OF CONNECTICUT (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023212027-A2 | GENETIC SEQUENCE-CARBOHYDRATE CONJUGATES FOR ENHANCED LIVER- AND KIDNEY-SPECIFIC TARGETING | UNIVERSITY OF CONNECTICUT (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230304014-A1 | MIRNA-485 INHIBITOR FOR HUNTINGTON'S DISEASE | BIORCHESTRA CO., LTD. (KR) | 2023-09-28 | — | — | US | disclosed |
| US-20230277658-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING | YALE UNIVERSITY (US) | 2023-09-07 | — | — | US | disclosed |
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-08-29 | — | — | US | disclosed |
| US-20230256119-A1 | COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA | BIORCHESTRA CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-11702660-B2 | Modulation of gene expression and screening for deregulated protein expression | UNIVERSITY OF SOUTHAMPTON (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20090011957-A1 | Ligational encoding using building block oligonucleotides | NUEVOLUTION A/S (DK) | 2009-01-08 | — | — | US | disclosed |
| US-20090005335-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-01-01 | — | — | US | disclosed |
| US-20080318894-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 | SANTARIS PHARMA A/S (DK) | 2008-12-25 | — | — | US | disclosed |
| US-20080305957-A1 | Method for Obtaining Structural Information Concerning an Encoded Molecule and Method for Selecting Compounds | NUEVOLUTION A/S (DK) | 2008-12-11 | — | — | US | disclosed |
| US-7452673-B2 | Photoacid generators for the synthesis of oligo-DNA in a polymer matrix | AFFYMETRIX, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7413854-B2 | Method for synthesising templated molecules | NUEVOLUTION A/S (DK) | 2008-08-19 | — | — | US | disclosed |
| US-20080188432-A1 | Short nucleotide subsequences located within number 15; such as locked nucleic acids antisense oligonucleotides; biostability, cell permeability; anticancer agents | SANTARIS PHARMA A/S (DK) | 2008-08-07 | — | — | US | disclosed |
| US-20070265366-A1 | Photoacid Generators For The Synthesis of Oligo-DNA in a Polymer Matrix | AFFYMETRIX, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070191294-A1 | Short interfering rna (sirna) analogues | SANTARIS PHARMA A/S | 2007-08-16 | — | — | US | disclosed |
| US-20070026397-A1 | Method for producing second-generation library | NUEVOLUTION A/S (DK) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277658-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TRIPLEX AND NUCLEASE-BASED GENE EDITING | DNASE1L3, DNASE1, DCLRE1B | PRMT3 2925/4885CARM1 2022/4885PRMT6 3615/4885 |
| US-20090005335-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | CTNNB1, CTNNA1, WNT1 | PRMT3 2419/4885CARM1 3175/4885PRMT6 2481/4885 |
| US-20230256119-A1 | COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA | APP, PSEN2, PSEN1 | PRMT3 1298/4885CARM1 773/4885PRMT6 1140/4885 |
| US-20070265366-A1 | Photoacid Generators For The Synthesis of Oligo-DNA in a Polymer Matrix | POLN, POLH, POLI | PRMT3 4764/4885CARM1 4838/4885PRMT6 4350/4885 |
| US-11833254-B2 | Discoidal nano universal platform for efficient delivery of PNAs | PHOSPHO1, PNLIP, DNTT | PRMT3 4432/4885CARM1 4774/4885PRMT6 4520/4885 |
| US-20080188432-A1 | Short nucleotide subsequences located within number 15; such as locked nucleic acids antisense oligonucleotides; biostability, cell permeability; anticancer agents | HRAS, KRAS, RNASE1 | PRMT3 4112/4885CARM1 2777/4885PRMT6 3705/4885 |
| US-20230304014-A1 | MIRNA-485 INHIBITOR FOR HUNTINGTON'S DISEASE | HTT, HIPK1, HIPK4 | PRMT3 1627/4885CARM1 439/4885PRMT6 724/4885 |
| US-20240067965-A1 | ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9 | PCSK9, SCD5, PCSK7 | PRMT3 2241/4885CARM1 2575/4885PRMT6 2643/4885 |
| US-20070191294-A1 | Short interfering rna (sirna) analogues | SNRPE, SNRPF, SNRPA | PRMT3 2176/4885CARM1 2958/4885PRMT6 2035/4885 |
| US-11912779-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MYOF, MTPN, PYGM | PRMT3 778/4885CARM1 1109/4885PRMT6 710/4885 |
| US-20080318894-A1 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3 | ERBB3, EGFR, ERBB2 | PRMT3 566/4885CARM1 2010/4885PRMT6 1765/4885 |
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | PCSK9, PCSK7, PCSK6 | PRMT3 3748/4885CARM1 4372/4885PRMT6 4170/4885 |
| US-11839624-B2 | Micellar nanoparticles and uses thereof | TLR9, HNRNPLL, POLRMT | PRMT3 1775/4885CARM1 1923/4885PRMT6 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.